MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Mirati Therapeutics Company Profile (NASDAQ:MRTX)

Consensus Ratings for Mirati Therapeutics (NASDAQ:MRTX) (?)
Ratings Breakdown: 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $29.63 (65.78% upside)

Analysts' Ratings History for Mirati Therapeutics (NASDAQ:MRTX)
Show:
DateFirmActionRatingPrice TargetActions
5/24/2016WedbushReiterated RatingOutperform$41.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Piper JaffrayInitiated CoverageHold$20.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Jefferies GroupReiterated RatingBuy$29.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Avondale PartnersUpgradeMarket Perform -> Market Outperform$22.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016Leerink SwannLower Price TargetOutperform$50.00 -> $37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016SunTrustInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetBuy$50.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$48.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2014Johnson RiceUpgradeOverweight -> Focus ListView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2014JMP SecuritiesReiterated RatingMarket Outperform$25.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha